https://www.selleckchem.com/pr....oducts/oxidopamine-h
ynchronous activity associated with seizures. PD-1/PD-L1 antibodies have achieved great success in clinical treatment. However, monoclonal antibody drugs also have challenges, such as high manufacturing costs, poor diffusion, low oral bioavailability and limited penetration into tumour tissue. The development of small-molecule inhibitors of PD-1/PD-L1 interaction represents a promising perspective to overcome the above challenges in cancer immunotherapy. We explored structural activity relationships and used biochemical
Like
Comment
Share
